Treatment options for painful knee osteoarthritis (OA) are numerous, but comparative outcomes are seldom available. A NEJM report shows that physical therapy is superior to intraarticular glucocorticoids injections assessing the outcomes 12 months after the intervention.
The presentations of the COVID-19 infection have been clearly chronicled with the worrisome onset of sore throat, dry cough, loss of smell and taste with fevers, myalgias, fatigue and the worrisome progression of pulmonary involvement in a minority. Lab findings may include a leukocytosis,
The Journal of Rheumatology reports a retrospective, single center, analysis of 17 rheumatoid vasculitis patients who responded well to intravenous rituximab (RTX) therapy.
On April 11th, the ACR Board of Directors approved a COVID-19 guidance document written by an ACR task force charged with updating and clarifying recommendations for rheumatologists and rheumatic disease patient management during the current COVID-19 crisis.
The 9/11/01 terrorist attach on the World Trade Center (WTC) resulted in at least 2,977 fatalities, over 25,000 injuries, and caused at least $10 billion in infrastructure and property damage. Arthritis & Rheumatology reports that dust cloud exposure among responders and
The monoclonal antibody guselkumab (Tremfya), which binds the interleukin (IL)-23 p19 subunit, was effective for psoriatic arthritis in two large clinical trials, providing comprehensive benefits for this heterogeneous disorder, investigators reported in The Lancet.
Dr Jack Cush reviews the news and journal reports from the past week on RheumNow.com
The New England Journal of Medicine has featured a report of three COVID infected patients, who developed peripheral and central infarcts with a antiphospholipid antibodies.
On Tuesday, April 7th, RheumNow hosted its first Tuesday Nite Rheumatology webinar - kicking off a two-month series of Rheumatology Grand Rounds lectures. The first session featured Jack Cush, MD (UT Southwestern) who lectured on "The Safety of Biologics and Newer Agents".
The incubation period for coronavirus disease 2019 (COVID-19) has important implications for surveillance and control activities. The Annals of Internal Medicine reports a pooled analysis of confirmed COVID-19 cases January 4, 2020 and February 24, 2020.
A phase III study of the nerve growth factor and monoclonal antibody tanezumab showed positive results in a refractory patient population with knee or hip osteoarthritis (OA) -- good enough that this agent may finally be approved after a long and rocky development road.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
